A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.-Reference-Cited by-同舟云学术

A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.

Published:1993-11-01 Issue:11 Volume:56 Page:1157-1163
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:Journal of Neurology, Neurosurgery & Psychiatry

Author:

Publisher

BMJ

Subject

Psychiatry and Mental health,Clinical Neurology,Surgery

Reference19 articles.

1. The course of myasthenia gravis and therapies affecting outcome;Grob, D.; Arsura, E.L.; Brunner, N.G.; Namba, T.;Biology and treatment. Ann N YAcad Sci,1987

2. Myasthenia gravis;Oosterhuis, H.J.,1984

3. High dose daily prednisone in the treatment of myasthenia gravis;Sanders, D.B.; Howard, F.J.; Johns, T.R.; Campa, J.F.,1979

4. Controversies about the treatment of myasthenia gravis;Rowland, L.P.;J Neurol Neurosurg Psychiatry,1980

5. Long term corticosteroid treatment of myasthenia gravis;Pascuzzi, R.M.; Coslett, H.B.; Johns, T.R.;Ann Neurol,1984

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations;Scientific Reports;2024-03-27

2. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study;The Lancet Neurology;2024-03

3. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study;Acta Neurologica Belgica;2023-09-01

4. Childhood myasthenia gravis in Japan: Pathophysiology and treatment options;Clinical and Experimental Neuroimmunology;2023-07-19

5. On the path to evidence-based therapy in neuromuscular disorders;Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders;2023